ClinicalIntelPulse · Clinical Deal Signal

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "acquisition_targets": [
    {
      "asset": "Mazdutide (IBI362)",
      "clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
      "company": "Innovent Biologics (China)",
      "deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
      "deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
      "estimated_deal_value_usd_m": "800-2000",
      "mechanism": "GLP-1/glucagon dual agonist",
      "probability": "High",
      "risks": [
        "China geopolitical risk for IP transfer",
        "Phase 3 US/EU data needed before deal close"
      ],
      "stage": "PHASE3"
    }
  ],
  "deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
  "licensing_opportunities": [
    {
      "asset": "CT-388 (dual GLP-1/GIP)",
      "company": "Carmot Therapeutics (acq. Roche)",
      "estimated_license_value_usd_m": "300-800",
      "notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm"
    }
  ],
  "market_context": {
    "approved_leaders": [
      "Semaglutide (Novo Nordisk — Wegovy)",
      "Tirzepatide (Lilly — Zepbound)"
    ],
    "big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
    "total_addressable_market_usd_bn": 100
  },
  "query_summary": {
    "as_of": "2026-06-07",
    "condition": "Obesity",
    "deal_type": "both",
    "stage": "both"
  },
  "recent_deal_comps": [
    {
      "deal": "Roche / Carmot Therapeutics",
      "mechanism": "GLP-1 peptide",
      "stage": "PHASE1/2",
      "value_usd_bn": 2.7,
      "year": 2023
    },
    {
      "deal": "AstraZeneca / Eccogene",
      "mechanism": "Small-molecule GLP-1",
      "stage": "PHASE2",
      "value_usd_bn": 1.85,
      "year": 2024
    },
    {
      "deal": "Amgen / ChemoCentryx",
      "mechanism": "C5aR1",
      "stage": "Approved",
      "value_usd_bn": 3.7,
      "year": 2022
    }
  ]
}